search

Active clinical trials for "Gastrointestinal Neoplasms"

Results 21-30 of 614

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain...

Brain CancerBrain Metastases14 more

The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.

Recruiting20 enrollment criteria

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Solid NeoplasmsColorectal Neoplasms1 more

The primary objective of this study is to assess the safety and tolerability of E7386 in participants with solid tumor including CRC.

Recruiting42 enrollment criteria

A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal...

Gastrointestinal Cancer

This study is a prospective single-arm phase II clinical study. Advanced Gastrointestinal cancer (excluding Biliary Tract Cancer) patients with FGFR 1-3 alterations who have failed standard therapy will be enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening. The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 12 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0.

Recruiting40 enrollment criteria

Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With...

Advanced Solid TumorsDigestive System Neoplasms2 more

This is a open-label, single center to determine the efficacy and safety of IM96 CAR-T cells in Patients With Advanced Digestive System Neoplasms

Recruiting29 enrollment criteria

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From...

Peritoneal CarcinomatosisPeritoneal Metastases6 more

The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a monocentric, phase I trial.

Recruiting20 enrollment criteria

Treatment Recommendations for Gastrointestinal Cancers Via Large Language Models

Gastrointestinal Neoplasm Malignant

This study will evaluate the utility of ChatGPT in recommending treatment plans for patients with gastrointestinal cancers, using both retrospective and prospective data.

Recruiting6 enrollment criteria

Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations

Gastrointestinal Cancer

This study is a prospective single-arm phase II study to evaluate the efficacy and safety of Pemigatinib in the advanced gastrointestinal cancer with FGFR 1-3 alterations and failed standard therapy.

Recruiting38 enrollment criteria

GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite...

Gastric CancerPancreatic Cancer

Phase I Part : Confirm the safety of GAIA-102 GAIA-102 as a single agent or GAIA-102 and pembrolizumab in combination for Advanced gastrointestinal cancer of microsatellite stable with malignant ascites, and determine the recommended number of doses for Phase II part. Phase II Part : Research the efficacy and safety of as a single agent or GAIA-102 and pembrolizumab for Advanced gastrointestinal cancer of microsatellite stable with malignant ascites at the recommended dose of GAIA-102 decided in the Phase I part.

Recruiting49 enrollment criteria

Treatment of ARB202 Advanced Gastrointestinal Cancer Patients

Gastrointestinal CancerCholangiocarcinoma4 more

This study aims to find out: The tolerability of ARB202 in adults with advanced solid gastrointestinal tumors who failed the standard treatment. People can participate if their tumor has the CDH17 marker. To find out how study drug is broken down in the body To know the effects of the study drug on the tumor.

Recruiting33 enrollment criteria

Total Versus Partial Omentectomy in the Treatment of Gastric Cancer

Stomach NeoplasmsInterleukin3 more

The main purpose of this study is to evaluate the role of the type of omentectomy (partial or total) in the treatment of Tis - T3 gastric cancer without serosal infiltration. The second purpose is to monitoring the blood levels of immunological factors (interleukins, T cell subtypes, etc.) pre-and postoperatively, depending on the type of omentectomy.

Recruiting11 enrollment criteria
1234...62

Need Help? Contact our team!


We'll reach out to this number within 24 hrs